Michael Nemunaitis

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

John Nemunaitis, Alex W. Tong, Michael Nemunaitis et al. · Molecular Therapy · 2009 · 265 citations · Full text

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

John Nemunaitis, Michael Nemunaitis, Neil Senzer et al. · Cancer Gene Therapy · 2009 · 146 citations

Allogeneic Tumor Vaccine, Tgf-β2 Antisense Gene, Tumor Immunology +9

Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer

Minal Barve, James Bender, Neil Senzer et al. · Journal of Clinical Oncology · 2008 · 98 citations

<i>p53</i> therapy in a patient with Li-Fraumeni syndrome

Neil Senzer, John Nemunaitis, Michael Nemunaitis et al. · Molecular Cancer Therapeutics · 2007 · 54 citations

Proof concept for clinical justification of network mapping for personalized cancer therapeutics

John Nemunaitis, Neil Senzer, Iya Khalil et al. · Cancer Gene Therapy · 2007 · 20 citations

Proof Concept, Network Science, Engineering +14